News

Thanks to the GLP-1 receptor agonists and newer, related drugs, it’s now possible to go beyond the traditional glucocentric model of diabetes treatment and address obesity too. The implications of this...

Obstructive sleep apnoea, with its various health consequences, is more common among people with type 2 diabetes than those without the condition. A new study, reported in a recent issue of Diabetologia, fin...

Bariatric surgery can lead to health benefits in type 2 diabetes that go way beyond weight loss and remission. The latest findings in this area were presented at the recent ADA conference, making a strong ca...

A new study in a recent issue of Diabetologia compares intermittent (flash) glucose monitoring with finger-prick testing in a group of pregnant women with type 1 diabetes. While flash did improve glycaemic c...

Counselling and pharmacotherapy can each of them aid weight loss in people with obesity. So what happens when you combine the two? Lisa Buckingham reports on the case for pairing these interventions, as pres...

Tirzepatide is a new class of drug for management of type 2 diabetes. A meta-analysis of its glucose-lowering and weight-loss effects, presented in a recent issue of Diabetologia, will help guide treatment d...

Diabetes is one established risk factor for dementia among many others, so what kind of interventions can reduce risk? This question was addressed at the ADA’s latest conference. Lisa Buckingham reports.

A new analysis of the Global Burden of Disease study, presented in a recent issue of Diabetologia, reveals the geographical variation of type 2 diabetes and how risk factors for the associated morbidity and ...

The centrality of disrupted beta cell function to type 1 diabetes is widely understood. Less commonly appreciated is the vital part it plays in type 2 – a role that takes centre stage in Professor Hind...

Food insecurity is prevalent across the globe, with far-reaching consequences for people’s health and well-being – consequences that can be significantly exacerbated for young people with diabete...

Statins are often prescribed to people with diabetes to reduce their risk of cardiovascular disease. But some clinical trials have reported cases of new-onset diabetes among statin users. Dr Susan Aldridge r...

Plant-based eating is a hot topic and ‘Just how plant-based should people with diabetes go?’ was a question addressed at the ADA’s latest conference. Lisa Buckingham reports.

Insulin allergy can cause significant challenges in diabetes treatment. A new paper in Diabetologia discusses the diagnosis and management of this rare, but important, condition. Dr Susan Aldridge reports.

For the latest in our series ‘The long and the short of it’, renowned psychologists with a specialism in diabetes, Professors Bill Polonsky (University of California, USA) and Frank Snoek (Amster...

Low-calorie sweeteners were under the spotlight at the ADA’s 82nd Scientific Sessions. Lisa Buckingham reports.

A new analysis from the Adolescent Cardio-Renal Intervention Trial, reported in a recent issue of Diabetologia, shows that higher urinary albumin/creatinine ratio – even within the normal range –...

Learner feedback helps to ensure that the EASD e-Learning programme is up to date, evidence based and meets the needs of learners. It is also important that learners know their feedback is taken seriously. D...

Lowering LDL cholesterol to reduce cardiovascular risk is strongly recommended for people with type 1 diabetes. A new risk score to guide statin prescribing was under discussion at the recent at the recent A...

Patient education and support are crucial for effective diabetes management, right? So far, so uncontroversial – but what should that education encompass? Who should provide it, where and when? These a...

The traditional classification of diabetes, which assigns most cases as type 1 and type 2, fails to capture the complexity of the condition. The latest research on clustering and subtyping, presented at the ...

A new study, reported in a recent issue of Diabetologia, shows that dapagliflozin benefits people across a wide range of kidney disease severity. The findings, based on an analysis of the DAPA-CKD trial, tak...